Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker.
Academic Article
Overview
Research
Identity
Additional Document Info
Other
View All
Overview
abstract
INTRODUCTION: Plasma levels of amyloid-beta (A) do not correlate well with different stages of Alzheimer's disease (AD) in cross-sectional studies. Measuring the changes in A plasma levels with an acute intervention may be more sensitive to distinguishing individuals in earlier stages of AD (mild cognitive impairment; MCI) from normal controls. METHODS: 57 participants (18 with AD/MCI and 39 cognitively normal controls) underwent oral glucose tolerance testing (OGTT). Blood samples were obtained over a 2 hour time period. Changes in plasma A40 and42 levels were measured from either baseline or 5 minutes to the 10 minute time point. RESULTS: Compared to normal controls, subjects with AD/MCI had significantly less change () in plasma levels for both A40(-3.13(40.93)pg/ml vs. 41.34(57.16)pg/ml;p=0.002) and A42(-0.15(3.77)pg/ml vs. 5.64(10.65)pg/ml; p=0.004). DISCUSSION: OGTT combined with measures of plasma A40 and 42 is potentially useful in distinguishing aging individuals who are in different stages of AD.
Oh, E. S., Marano, C. M., Leoutsakos, J., Lee, R. W., Rissman, R. A., Smith, G. S., Craft, S., & Lyketsos, C. G.
citation count
1
complete list of authors
Oh, Esther S||Marano, Christopher M||Leoutsakos, Jeannie-Marie||Lee, Rebecca W||Rissman, Robert A||Smith, Gwenn S||Craft, Suzanne||Lyketsos, Constantine G